ES483077A0 - Un procedimiento para la obtencion de un derivado de tiazo- lidina - Google Patents

Un procedimiento para la obtencion de un derivado de tiazo- lidina

Info

Publication number
ES483077A0
ES483077A0 ES483077A ES483077A ES483077A0 ES 483077 A0 ES483077 A0 ES 483077A0 ES 483077 A ES483077 A ES 483077A ES 483077 A ES483077 A ES 483077A ES 483077 A0 ES483077 A0 ES 483077A0
Authority
ES
Spain
Prior art keywords
lidina
tiazo
derivative
procedure
obtaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES483077A
Other languages
English (en)
Spanish (es)
Other versions
ES8102107A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14144012&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES483077(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of ES8102107A1 publication Critical patent/ES8102107A1/es
Publication of ES483077A0 publication Critical patent/ES483077A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES483077A 1978-08-04 1979-08-02 Un procedimiento para la obtencion de un derivado de tiazo- lidina Granted ES483077A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9567378A JPS5522636A (en) 1978-08-04 1978-08-04 Thiazoliding derivative

Publications (2)

Publication Number Publication Date
ES8102107A1 ES8102107A1 (es) 1980-12-16
ES483077A0 true ES483077A0 (es) 1980-12-16

Family

ID=14144012

Family Applications (1)

Application Number Title Priority Date Filing Date
ES483077A Granted ES483077A0 (es) 1978-08-04 1979-08-02 Un procedimiento para la obtencion de un derivado de tiazo- lidina

Country Status (7)

Country Link
US (4) US4287200A (show.php)
EP (1) EP0008203B1 (show.php)
JP (1) JPS5522636A (show.php)
CA (1) CA1131644A (show.php)
DE (1) DE2963585D1 (show.php)
DK (1) DK149023C (show.php)
ES (1) ES483077A0 (show.php)

Families Citing this family (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
AU6610081A (en) * 1980-01-24 1981-07-30 Senju Pharmaceutical Co., Ltd. Thiazolidine derivatives
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
WO1985004170A1 (fr) * 1984-03-21 1985-09-26 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, leur procede de preparation et compositions medicinales les contenant
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
JPS6143114A (ja) * 1984-08-03 1986-03-01 Takeda Chem Ind Ltd 虹彩・毛様体疾患治療用眼局所投与剤
WO1986002073A1 (fr) * 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, procede de preparation et composition pharmaceutique les contenant
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
HU210339B (en) * 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
US4738972A (en) * 1985-05-21 1988-04-19 Pfizer Inc. Hypoglycemic thiazolidinediones
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US5691367A (en) * 1985-08-09 1997-11-25 Eli Lilly And Company Aryl-substituted rhodanine derivatives
US5356917A (en) * 1985-08-09 1994-10-18 Eli Lilly And Company Aryl-substituted rhodanine derivatives
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
JPS63230689A (ja) * 1987-03-18 1988-09-27 Tanabe Seiyaku Co Ltd ベンゾオキサジン誘導体
WO1988009661A1 (en) * 1987-06-10 1988-12-15 Pfizer Inc. Oxazolidin-2-one derivatives as hypoglycemic agents
EP0295828A1 (en) * 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
DE10199003I1 (de) * 1987-09-04 2003-06-12 Beecham Group Plc Substituierte Thiazolidinionderivate
US5521201A (en) * 1987-09-04 1996-05-28 Beecham Group P.L.C. Method for treatment of atherosclerosis
US4798835A (en) * 1987-12-02 1989-01-17 Pfizer Inc. dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US5120754A (en) * 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5130379A (en) * 1988-03-08 1992-07-14 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
WO1989008650A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB8919417D0 (en) 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
US5053420A (en) * 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5036079A (en) * 1989-12-07 1991-07-30 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5216002A (en) * 1989-12-21 1993-06-01 Eli Lilly And Company Method of treating inflammatory bowel disease
US5143930A (en) * 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
WO1991012003A1 (en) * 1990-02-09 1991-08-22 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
DE69132713D1 (de) * 1990-04-27 2001-10-11 Sankyo Co Benzylidenthiazolidinderivate, ihre Herstellung und ihre Anwendung als Lipidperoxid-Inhibitoren
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
CA2087437A1 (en) * 1990-08-23 1992-02-24 Steven W. Goldstein Hypoglycemic hydroxyurea derivatives
JPH0445604U (show.php) * 1990-08-24 1992-04-17
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023584D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5158966A (en) * 1991-02-22 1992-10-27 The University Of Colorado Foundation, Inc. Method of treating type i diabetes
JP3053490B2 (ja) * 1991-02-25 2000-06-19 杏林製薬株式会社 チアゾリジン−２，４−ジオン誘導体とその塩及び製造法
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
HUT68370A (en) * 1991-04-11 1995-06-28 Takeda Chemical Industries Ltd Thiazolidine derivatives, pharmaceutical compositions containing them and process for their production
TW222626B (show.php) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
NO302519B1 (no) * 1991-12-26 1998-03-16 Sankyo Co Tiazolidinforbindelser som inneholder en kinongruppe, og farmasöytisk preparat
NO302471B1 (no) * 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5498621A (en) * 1992-05-01 1996-03-12 Pfizer Inc. Oxazolidinedione hypoglycemic agents
DK0590793T3 (da) * 1992-08-31 2000-01-31 Sankyo Co Oxazolidin-derivater med anti-diabetiske og anti-obesitas-egenskaber, fremstilling deraf samt deres terapeutiske anvendelse
EP0915090A1 (en) * 1992-09-10 1999-05-12 Eli Lilly And Company Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
FR2696743B1 (fr) * 1992-10-12 1994-12-23 Adir Nouveaux composés de thiazolidine dione, leur procédé de préparation et les compositions pharmaceutiques les contenant.
TW245716B (show.php) * 1992-12-28 1995-04-21 Takeda Pharm Industry Co
US5591862A (en) * 1993-06-11 1997-01-07 Takeda Chemical Industries, Ltd. Tetrazole derivatives, their production and use
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
CA2171827C (en) * 1993-09-15 2004-06-29 Jerrold Olefsky Use of thiazolidinediones to prevent or delay onset of niddm
AU749416B2 (en) * 1993-09-15 2002-06-27 Daiichi Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of NIDDM
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5401761A (en) * 1993-12-09 1995-03-28 Pfizer, Inc. Thiazolidinedione hypoglycemic agents
US6251928B1 (en) 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
CA2145257A1 (en) * 1994-03-23 1995-09-24 Takashi Fujita Thiazolidine and oxazolidine derivatives, their preparation and their medical use
CA2146701A1 (en) * 1994-04-11 1995-10-12 Takashi Fujita Heterocyclic compounds having anti-diabetic activity, their preparation and their use
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5703096A (en) * 1994-10-07 1997-12-30 Sankyo Company, Limited Oxime derivatives, their preparation and their therapeutic use
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
JPH09136877A (ja) * 1995-06-16 1997-05-27 Takeda Chem Ind Ltd 複素環化合物、その製造法及び用途
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
AU706628B2 (en) * 1995-07-03 1999-06-17 Sankyo Company Limited Treatment of arteriosclerosis and xanthoma
AU7604596A (en) * 1995-11-17 1997-06-11 Warner-Lambert Company A method of treating myotonic dystrophy
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
ATE252074T1 (de) * 1996-04-04 2003-11-15 Sankyo Co Phenylalkylcarbonsäure-derivate
JPH09323930A (ja) 1996-04-04 1997-12-16 Takeda Chem Ind Ltd 悪液質の予防・治療剤
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
CA2257284C (en) * 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
FR2749583B1 (fr) * 1996-06-07 1998-08-21 Lipha Nouveaux derives de thiazolidine -2,4- dione substitues, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
US6114526A (en) 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
KR100579765B1 (ko) * 1996-07-01 2006-12-28 닥터 레디스 레보러터리즈 리미티드 신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도
JP2000514041A (ja) * 1996-07-26 2000-10-24 ドクター・レディーズ・リサーチ・ファウンデーション 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
DE19711617A1 (de) * 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Neue Thiazolidindione, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SE9702305D0 (sv) * 1997-06-17 1997-06-17 Astra Ab New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
EP1787646A3 (en) * 1997-06-18 2007-10-03 Smithkline Beecham Plc Novel method of treatment
KR20010013840A (ko) 1997-06-18 2001-02-26 피터 기딩스 티아졸리딘디온 및 술포닐우레아를 사용한 당뇨병의 치료
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
BR9813019A (pt) 1997-10-02 2000-09-05 Sankyo Co Derivados do ácido amidocarboxìlico, agentes para diminuir a glicose do sangue, redutor de lipìdio, para melhorar a resistência à insulina, anti-inflamatório, para imuno regulagem, para inibir a aldose reductase, para inibir a 5-lipoxigenase, para a geração de supressor de peróxido de lipìdio, para ativar a ppar, para minorar a osteoporose, e, composições para a terapia ou prevenção da diabete melito, da hiperlipemia, da obesidade, da tolerância à glicose prejudicada, da resistência à insulina que não a igt, do fìgado gorduroso, de complicações diabéticas, da arterioesclerose, da diabete melito gestacional, da sìndrome do ovário policìstico, da artroesteìte, da artrite reumática, de doenças alérgicas, da asma, do câncer, de doenças auto imunes, da pancreatite, e de cataratas
GB9723295D0 (en) 1997-11-04 1998-01-07 Smithkline Beecham Plc Novel process
US7091359B2 (en) 1997-11-04 2006-08-15 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives
HUP9902721A2 (hu) 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
TR200101333T2 (tr) * 1998-11-12 2001-10-22 Smithkline Beecham P.L.C. Bir ensülin sensitizörü ve başka bir anti-diyabetik maddenin değiştirilmiş salımı için farmasötik terkip.
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
WO2000030628A2 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism
WO2000043007A1 (en) * 1999-01-19 2000-07-27 Sankyo Company, Limited Troglitazone-containing medicinal compositions for inhibiting apoptosis
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US6127394A (en) * 1999-03-08 2000-10-03 The University Of Mississippi 1,2-Dithiolane derivatives
JP2002541129A (ja) 1999-04-01 2002-12-03 エスペリオン セラピューティクス インコーポレイテッド エーテル化合物、組成物、およびそれらの使用
US6214842B1 (en) 1999-05-12 2001-04-10 Michael S. Malamas Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia
ES2277842T3 (es) * 1999-06-18 2007-08-01 MERCK & CO., INC. Derivados de ariltiazolidindiona y de ariloxazolidindiona.
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
HK1043113A1 (zh) * 1999-07-01 2002-09-06 Geron Corporation 端粒酶抑制劑及其使用方法
CO5200844A1 (es) 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US20040266834A1 (en) * 1999-10-14 2004-12-30 Copland John A. Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy
US20080108825A1 (en) * 1999-11-08 2008-05-08 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
WO2001052789A2 (en) 2000-01-20 2001-07-26 The Brigham And Women's Hospital, Inc. PAX8-PPARη NUCLEIC ACID MOLECULES AND POLYPEPTIDES AND USES THEREOF
CA2673615C (en) 2000-01-21 2013-07-16 Novartis Ag Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
US20080103302A1 (en) * 2000-02-04 2008-05-01 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US6958355B2 (en) * 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6680387B2 (en) * 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
AU2001294673A1 (en) * 2000-09-21 2002-04-02 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
US20040122091A1 (en) * 2000-10-11 2004-06-24 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US6713507B2 (en) 2000-10-11 2004-03-30 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
US6703422B2 (en) 2000-10-11 2004-03-09 Esperion Therapeutics, Inc. Sulfide and disulfide compounds and compositions for cholesterol management and related uses
AU2002213136B2 (en) 2000-10-11 2007-01-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US7304093B2 (en) * 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
CN1479721A (zh) 2000-10-11 2004-03-03 ͨ��ҽ�ƹ�˾ 用于胆固醇治疗和相关应用的亚砜和双亚砜化合物和组合物
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
WO2002072146A2 (en) * 2001-03-12 2002-09-19 Novartis Ag Combination of nateglinide or repaglinide with at least one further antidiabetic compound
US20060047000A1 (en) * 2001-04-24 2006-03-02 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
JP4152641B2 (ja) * 2001-08-07 2008-09-17 クラシエ製薬株式会社 チアゾリジン誘導体の副作用軽減剤
US20040204502A1 (en) * 2001-10-11 2004-10-14 Dasseux Jean-Louis Henri Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20050020694A1 (en) * 2001-10-11 2005-01-27 Dasseux Jean-Louis Henri Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US20040192771A1 (en) * 2001-10-11 2004-09-30 Dasseux Jean-Louis Henri Ether compounds and compositions for cholesterol management and related uses
ITRM20020016A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
WO2003087108A2 (en) * 2002-04-10 2003-10-23 Esperion Therapeutics, Inc. Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses
BR0312426A (pt) * 2002-07-03 2005-12-06 Esperion Therapeutics Inc Composição farmacêutica, métodos para tratar, prevenir ou controlar um colesterol, dislipidemia ou distúrbio relacionado, para reduzir ou evitar um efeito adverso associado com monoterapia de pantetina e para reduzir ou evitar um efeito adverso associado com monoterapia de segundo agente ativo, e, kit
WO2004007490A2 (en) * 2002-07-16 2004-01-22 Cadila Healthcare Limited A process to prepare pioglitazone via several intermediates.
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US20040048910A1 (en) * 2002-08-22 2004-03-11 Bove Susan Elizabeth Method of treating osteoarthritis
WO2004067489A2 (en) * 2003-01-23 2004-08-12 Esperion Therapeutics, Inc. Hydroxyl compounds and compositions for cholesterol management and related uses
US7230016B2 (en) * 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
CN1812988A (zh) * 2003-05-13 2006-08-02 斯索恩有限公司 制备噻唑烷二酮衍生物的方法及其化合物
US20050107387A1 (en) * 2003-05-13 2005-05-19 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
BRPI0410840A (pt) * 2003-05-30 2006-07-04 Ranbaxy Lab Ltd derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação
WO2005002557A1 (en) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
ATE428411T1 (de) * 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
US20050192347A1 (en) * 2003-12-23 2005-09-01 Dasseux Jean-Louis H. Urea and thiourea compounds and compositions for cholesterol management and related uses
EP1701931B1 (en) 2003-12-24 2018-10-10 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
EP1716144A2 (en) * 2004-02-20 2006-11-02 Synthon B.V. Processes for making pioglitazone and compounds of the processes
US7161756B2 (en) * 2004-05-10 2007-01-09 Tandberg Data Storage Asa Method and system for communication between a tape drive and an external device
PE20060102A1 (es) * 2004-06-09 2006-02-09 Avanir Pharmaceuticals Pequenas moleculas para el tratamiento de hipercolesterolemia y enfermedades relacionadas
CN1968928A (zh) * 2004-06-09 2007-05-23 阿文尼尔药品公司 用于治疗高脂血症及相关疾病的杂环衍生物
JP2008509228A (ja) * 2004-06-09 2008-03-27 アバニール・ファーマシューティカルズ 高コレステロール血症の治療のための逆コレステロール輸送のメディエイタ
US20070269486A1 (en) * 2005-03-14 2007-11-22 Conor Medsystems, Llc. Methods and Devices for Reducing Tissue Damage After Ischemic Injury
EP1948599A1 (en) * 2005-11-08 2008-07-30 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
ES2388555T3 (es) 2006-03-16 2012-10-16 Metabolic Solutions Development Company Llc Análogos de tiazolidindiona
ES2397944T3 (es) 2006-03-16 2013-03-12 Metabolic Solutions Development Company Llc Análogos de tiazolidindiona
MX2009000439A (es) * 2006-07-14 2009-02-04 Ranbaxy Lab Ltd Formas polimorficas de un inhibidor de hmg-coa reductasa y usos de las mismas.
EP2134169A2 (en) 2007-03-09 2009-12-23 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
CA2688111A1 (en) 2007-05-23 2008-12-04 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
EP2203433B1 (en) * 2007-09-14 2012-10-31 Metabolic Solutions Development Company LLC 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione for use in treating diabetes
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
EP2383263B1 (en) * 2008-12-30 2014-04-16 Industry-academic Cooperation Foundation, Chosun University Novel thiazolidinedione derivative and use thereof
EP3358008A1 (en) 2009-09-03 2018-08-08 Pfizer Vaccines LLC Pcsk9 vaccine
ES2525748T3 (es) 2009-11-13 2014-12-29 Toray Industries, Inc. Agente terapéutico o profiláctico para la diabetes
US8912335B2 (en) 2009-12-15 2014-12-16 Metabolic Solutions Development Company, Llc PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases
AU2011207210A1 (en) 2010-01-22 2012-08-16 Dana-Farber Cancer Institute, Inc. Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
MX2012012095A (es) * 2010-04-21 2012-12-17 Metabolic Solutions Dev Co Llc Analogos de tiazolidinadiona.
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
EP2680883B1 (en) 2011-03-02 2018-09-05 Pfizer Inc Pcsk9 vaccine
US9623015B2 (en) 2012-11-05 2017-04-18 Commissariat À L'energie Atomique Et Aux Energies Alternatives (Cea) Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a STAT5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
EP3094328B1 (en) 2014-01-15 2020-08-19 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
CN107108710B (zh) 2014-10-24 2022-02-15 百时美施贵宝公司 修饰的fgf-21多肽及其用途
US10034868B2 (en) 2014-11-04 2018-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
MA42616A (fr) 2015-03-13 2021-05-19 Esperion Therapeutics Inc Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
CA3144372A1 (en) 2019-06-21 2020-12-24 Esperion Therapeutics, Inc. Salt forms of bempedoic acid and methods for using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3825553A (en) * 1970-05-05 1974-07-23 Rorer Inc William H Certain 5-arylthiazolidines
US3825587A (en) * 1970-05-05 1974-07-23 Rorer Inc William H Substituted phenylacetic acid compounds
CA962269A (en) * 1971-05-05 1975-02-04 Robert E. Grahame (Jr.) Thiazoles, and their use as insecticides
SU480711A1 (ru) * 1973-07-02 1975-08-15 Ленинградский Ордена Трудового Красного Знамени Технологический Институт Им.Ленсовета Способ получени производных 3-оксиметилтиазолиндиона-2,4
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative

Also Published As

Publication number Publication date
US4444779A (en) 1984-04-24
EP0008203B1 (en) 1982-08-25
JPS6242903B2 (show.php) 1987-09-10
ES8102107A1 (es) 1980-12-16
US4438141A (en) 1984-03-20
DE2963585D1 (en) 1982-10-21
EP0008203A1 (en) 1980-02-20
DK149023B (da) 1985-12-23
JPS5522636A (en) 1980-02-18
DK325079A (da) 1980-02-05
US4287200A (en) 1981-09-01
US4340605A (en) 1982-07-20
CA1131644A (en) 1982-09-14
DK149023C (da) 1986-10-13

Similar Documents

Publication Publication Date Title
ES483077A0 (es) Un procedimiento para la obtencion de un derivado de tiazo- lidina
ES490214A0 (es) Un procedimiento para la preparacion de derivados de feneta-nolamina
ES490503A0 (es) Un procedimiento para preparar nuevos compuestos de cefem
ES485619A0 (es) Un procedimiento para la preparacion de derivados de diben- zopirano
ES490212A0 (es) Un procedimiento para la preparacion de fenetanolaminas
ES492002A0 (es) Un procedimiento para preparar compuestos de cefem
ES486328A0 (es) Un procedimiento para preparar benzoxazepinas
ES484930A0 (es) Un procedimiento para la preparacion de fenil-quinolicidinas
AR223166A1 (es) Procedimiento para la obtencion de un catalizador
AR226031A1 (es) Procedimiento para la obtencion de un catalizador
ES484890A0 (es) Un procedimiento para la preparacion de derivados de ciclo- hexadieno
ES489048A0 (es) Un procedimiento para la preparacion de derivados de hidan- toina
ES500478A0 (es) Un procedimiento para obtener derivados de biciclooctano
ES535951A0 (es) Procedimiento para la obtencion de un derivado de tetrahidrobenzotiazol
ES486989A0 (es) Un procedimiento para preparar derivados de la 4- dehidropi-ridina.
ES489590A0 (es) Un procedimiento para preparar arilalquil- y ariloxi-alquil-fosfonatos
ES489648A0 (es) Un procedimiento para la preparacion de un derivado de cefa-losporina
ES490617A0 (es) Un procedimiento para la preparacion de derivados de oxadia-zolotriazona
ES492809A0 (es) Un procedimiento para obtener derivados de triciclohexiles- tano
ES487939A0 (es) Un procedimiento para obtener derivados de quinazolina
ES490615A0 (es) Un procedimiento para la preparacion de derivados de oxadia-zolotriazona
AR227094A1 (es) Un procedimiento para preparar un derivado de indolizina
ES486666A0 (es) Un procedimiento para la preparacion de carbetoxi-carbonila-mino-pirimidinas
AR225423A1 (es) Un procedimiento para la fabricacion de un derivado de 1-p-amino-alcoxifenil-1-p-aciloxifenil-2-fenil-alqueno-1
ES485300A0 (es) Un procedimiento para la obtencion de nitrilos